Gamida Cell (GMDA) Scheduled to Post Quarterly Earnings on Monday

Posted by Defense World Staff on Aug 12th, 2023

Gamida Cell (NASDAQ:GMDA – Get Free Report) is scheduled to be issuing its quarterly earnings data before the market opens on Monday, August 14th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Gamida Cell (NASDAQ:GMDA – Get Free Report) last issued its quarterly earnings results on Monday, May 15th. The company reported ($0.27) EPS for the quarter, hitting analysts’ consensus estimates of ($0.27). On average, analysts expect Gamida Cell to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Gamida Cell Price Performance

Shares of NASDAQ:GMDA opened at $1.22 on Friday. The company’s fifty day moving average price is $1.67 and its 200-day moving average price is $1.57. The firm has a market capitalization of $128.82 million, a price-to-earnings ratio of -2.10 and a beta of 1.52. Gamida Cell has a one year low of $0.56 and a one year high of $3.45.

Analyst Ratings Changes

A number of equities analysts have recently commented on GMDA shares. Needham & Company LLC decreased their price target on shares of Gamida Cell from $8.00 to $6.00 and set a “buy” rating on the stock in a report on Thursday, April 20th. HC Wainwright increased their target price on shares of Gamida Cell from $5.00 to $11.00 and gave the company a “buy” rating in a report on Wednesday, April 19th. Finally, JMP Securities reduced their target price on shares of Gamida Cell from $8.00 to $6.00 in a report on Friday, May 19th.

View Our Latest Report on GMDA

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of GMDA. Federated Hermes Inc. lifted its position in Gamida Cell by 17.5% during the 1st quarter. Federated Hermes Inc. now owns 5,128,300 shares of the company’s stock valued at $21,282,000 after acquiring an additional 764,985 shares during the period. Walleye Capital LLC bought a new stake in Gamida Cell during the 2nd quarter valued at about $312,000. Marshall Wace LLP increased its stake in Gamida Cell by 64.0% during the 3rd quarter. Marshall Wace LLP now owns 368,899 shares of the company’s stock valued at $586,000 after purchasing an additional 143,968 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Gamida Cell by 12.8% during the 1st quarter. JPMorgan Chase & Co. now owns 731,328 shares of the company’s stock valued at $3,035,000 after purchasing an additional 83,009 shares in the last quarter. Finally, Mariner LLC increased its stake in Gamida Cell by 8.3% during the 1st quarter. Mariner LLC now owns 621,334 shares of the company’s stock valued at $2,579,000 after purchasing an additional 47,587 shares in the last quarter. 56.24% of the stock is owned by hedge funds and other institutional investors.

About Gamida Cell

(Get Free Report)

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia.